Oncolytics appoints Steve Glover to board, promotes John McAdory to COO

ONCOLYTICS BIOTECH INC

Steve Glover appointed to board effective June 1, 2026; he chaired Ambrx during its $2B J&J acquisition.
John McAdory promoted to COO effective June 1, 2026; previously EVP Strategy & Operations since Jan 2026.
McAdory will oversee clinical ops, preclinical R&D, strategic partnerships, and business development.
Glover receives an option to purchase 96,000 shares vesting over three years; McAdory receives no extra compensation.
Glover brings 35+ years biopharma experience; also chairs ZyVersa Therapeutics and sits on PDS Biotech board.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John McAdory

Chief Operating Officer

ONCY · ONCOLYTICS BIOTECH INC

Effective: 2026-06-01
Filed: June 2, 2026, 9:02 AM ET

appointed John McAdory as Chief Operating Officer of the Company

Appointed

Stephen Glover

Director

ONCY · ONCOLYTICS BIOTECH INC

Effective: 2026-06-01
Filed: June 2, 2026, 9:02 AM ET

appointed Stephen Glover as the ninth director of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John McAdory was appointed as Chief Operating Officer at ONCOLYTICS BIOTECH INC.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

appointed John McAdory as Chief Operating Officer of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Glover was appointed as Director at ONCOLYTICS BIOTECH INC.

Action: appointed
Role: Director

Exact text from the filing

appointed Stephen Glover as the ninth director of the Board

View on SEC.gov

ONCOLYTICS BIOTECH INC filing history →

Source: SEC EDGAR

accession 0001129928-26-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.